Current Cardiology Reports

, Volume 9, Issue 2, pp 87–92

Are vasodilators still indicated in the treatment of severe aortic regurgitation?

Valvular Heart Disease

DOI: 10.1007/BF02938333

Cite this article as:
Inamo, J. & Enriquez-Sarano, M. Curr Cardiol Rep (2007) 9: 87. doi:10.1007/BF02938333
  • 32 Downloads

Abstract

Aortic regurgitation (AR) is a valve disease that causes severe complications and reduces life expectancy. Surgical correction is required in the late stages of the disease. In less advanced forms, treatment with vasodilators is a consideration. The available evidence suggests that this type of treatment has a favorable effect on the consequences of AR, particularly left ventricular remodeling. However, the impact of vasodilators on clinical endpoints complicating the course of AR remains in doubt. The limited evidence supporting or opposing the utilization of vasodilators in AR hinders drawing firm conclusions and emphasizes the process of individualized interpretation of the clinical presentation of patients with the disease.

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Division of Cardiovascular Diseases and Internal MedicineMayo ClinicRochesterUSA

Personalised recommendations